Read the interview with Jan van de Winkel about his keynote for the opening of Utrecht Science Week on September 26
At the opening of Utrecht Science Week, Prof. Dr. Jan van de Winkel will share how immunotherapy, AI, and collaboration are key to groundbreaking advances in fighting and preventing cancer and other serious diseases.
What does it mean to “crack the code on cancer and other serious diseases”?
For Prof. Dr. Jan van de Winkel, co-founder of Genmab and a global leader in antibody-based therapies, it is about unlocking the full potential of the immune system to fight and ultimately prevent diseases.
In his keynote at the opening of the Utrecht Science Week on September 26, he will share the latest breakthroughs in antibody science, cross-sector collaboration, and the role of AI in medicine. With decades of experience rooted in the Utrecht Science Park, Jan van de Winkel shows how innovation, partnerships, and a clear purpose come together to make a real impact for patients worldwide.
Students, young researchers, and healthcare professionals can expect a unique insight into the dynamic world of biotechnology and immunotherapy and how teamwork and perseverance can lead to life-changing treatments.
Read the full interview and get a preview of his keynote here
Register for the keynote here